Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics

References

• Mckenzie SB. Advances in understanding the biology and genetics of acute myeloid leukemia. Clin Lab Sci. 2005;18:28–37.
   PubMedGoogle Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French–American–British Cooperative Group. Ann Intern Med 1985;103:620–625.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Miyawaki S, Tanimoto M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/ intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 1996;14:204–213.
   PubMed Web of Science ®Google Scholar
• Miyawaki S, Tanimoto M, Kobayashi T, et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol 1999;70:97–104.
   PubMed Web of Science ®Google Scholar
• Mro'zek K, Heinonen K, de la Chapelle A, et al. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24:17–31.
   PubMed Web of Science ®Google Scholar
• Dohner K, Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008;93:976–982.
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074–3080.
   PubMed Web of Science ®Google Scholar
• Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?Immunol Today 1999;20:469–473.
   PubMedGoogle Scholar
• Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363–1372.
   PubMed Web of Science ®Google Scholar
• Murray HW, Szuro-Sudol A, Wellner D, et al. Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun 1989;57:845–849.
   PubMed Web of Science ®Google Scholar
• Fujigaki S, Saito K, Sekikawa K, et al. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 2001;31:2313–2318.
   PubMed Web of Science ®Google Scholar
• Fujigaki H, Saito K, Fujigaki S, et al. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 2006;139:655–662.
   PubMed Web of Science ®Google Scholar
• Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002;196:459–468.
   PubMed Web of Science ®Google Scholar
• Huang A, Fuchs D, Widner B, et al. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002;86:1691–1696.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Hara T, Tsurumi H, et al. Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 2010;84:304–309.
   PubMed Web of Science ®Google Scholar
• Ninomiya S, Hara T, Tsurumi H, et al. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 2011;90:409–416.
   PubMed Web of Science ®Google Scholar
• Ninomiya S, Hara T, Tsurumi H, et al. Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2012;53:1143–1145.
   PubMed Web of Science ®Google Scholar
• Arber DA, Brunning RD, Orazi A, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow S, Campo E, Harris NL, editors. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. pp 124–126.
   Google Scholar
• Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322–2333.
   PubMed Web of Science ®Google Scholar
• Hoshi M, Saito K, Hara A, et al. The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J Immunol 2010;185:3305–3312.
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Kuriyama K, Miyawaki S, et al.; Japan Adult Leukaemia Study Group. Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study. Br J Haematol 2003;120:56–62.
   PubMed Web of Science ®Google Scholar
• Tsurumi H, Kanemura N, Hara T, et al. Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide. J Cancer Res Clin Oncol 2007;133:547–553.
   PubMed Web of Science ®Google Scholar
• Kanemura N, Tsurumi H, Kasahara S, et al. Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy. Hematol Oncol 2008;26:33–38.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Chamuleau ME, van de Loosdrecht AA, Hess CJ, et al. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 2008;93:1894–1898.
   PubMed Web of Science ®Google Scholar
• Della Chiesa M, Carlomagno S, Frumento G, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 2006;108:4118–4125.
   PubMed Web of Science ®Google Scholar
• Ino K, Yoshida N, Kajiyama H, et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006;95:1555–1561.
   PubMed Web of Science ®Google Scholar
• Takao M, Okamoto A, Nikaido T, et al. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 2007;17:1333–1339.
   PubMed Web of Science ®Google Scholar
• Pan K, Wang H, Chen MS, et al. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008;134:1247–1253.
   PubMed Web of Science ®Google Scholar
• Curti A, Aluigi M, Pandolfi S, et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 2007;21:353–355.
   Google Scholar
• Curti A, Pandolfi S, Valzasina B, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25 + T regulatory cells. Blood 2007;109:2871–2877.
   PubMed Web of Science ®Google Scholar
• Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312–319.
   PubMed Web of Science ®Google Scholar
• Yoshida N, Ino K, Ishida Y, et al. Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res 2008;14:7251–7259.
   PubMed Web of Science ®Google Scholar
• Inaba T, Ino K, Kajiyama H, et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 2009;115:185–192.
   PubMed Web of Science ®Google Scholar
• Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792–801.
   PubMed Web of Science ®Google Scholar
• Jeong YI, Jung ID, Lee JS, et al. (–)-Epigallocatechin gallate suppresses indoleamine 2,3-dioxygenase expression in murine dendritic cells: evidences for the COX-2 and STAT1 as potential targets.Biochem Biophys Res Commun 2007;354:1004–1009.
   PubMed Web of Science ®Google Scholar
• Cheng CW, Shieh PC, Lin YC, et al. Indoleamine 2,3-dioxygenase, an immunomodulatory protein, is suppressed by (–)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells. J Agric Food Chem 2010;58:887–894.
   PubMed Web of Science ®Google Scholar
• Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002;42:25–54.
   PubMed Web of Science ®Google Scholar
• Rodriguez SK, Guo W, Liu L, et al. Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int J Cancer 2006;118:1635–1644.
   PubMed Web of Science ®Google Scholar
• Han C. Screening of anticarcinogenic ingredients in tea polyphenols. Cancer Lett 1997;114:153–158.
   PubMed Web of Science ®Google Scholar
• Surh YJ, Chun KS, Cha HH, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001;480-481:243–268.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link?Biochem Pharmacol 2006;72:1605–1621.
   PubMed Web of Science ®Google Scholar
• Shirakami Y, Shimizu M, Tsurumi H, et al. EGCG and polyphenon E attenuate inflammation-related mouse colon carcinogenesis induced by AOM and DSS. Mol Med Rep 2008;l:355–361.
   Google Scholar
• Ogawa K, Hara T, Shimizu M, et al. Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase. Cancer Sci 2012;103:951–958.
   PubMed Web of Science ®Google Scholar